Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT041 in Advanced Solid Tumors
NCT03874897Phase 1Completed
- Sponsor
- Peking University
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of satricabtagene autoleucel in gastric cancer (GC), esophagogastric junction cancer and pancreatic cancer (PC) (5 arms), sponsored by Peking University. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Started Mar 2019; status: completed.
02
Drugs
satricabtagene autoleucel
03
Conditions
gastric cancer (GC)esophagogastric junction cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03874897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874897.